Fig. 6

Tumour regrowth after 2 weeks of PLX4720 mono- or combination therapy coincided with a. An increase in F4/80⁺ myeloid cells with PLX4720, and a decrease in F4/80⁺ myeloid cells in combination-treated mice. Three weeks of combination therapy was associated with a further decrease in F4/80⁺ myeloid cells. b Two weeks of single or combination PLX4720 treatment did not lead to a significant change in the M1/M2 TAM populations, whereas 3 weeks of combination treatment was associated with a dramatic increase in the proportion of M2-polarised compared to M1-polarised TAMs. N = 4 mice per group, repeated twice